Lipocine, Inc. (LPCN)
1.615
+0.08
(+5.56%)
USD |
NASDAQ |
Nov 06, 10:23
Lipocine EPS Diluted (Quarterly) : -0.3192 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3192 |
| March 31, 2026 | -0.5404 |
| December 31, 2025 | -0.4158 |
| September 30, 2025 | -0.5887 |
| June 30, 2025 | -0.4121 |
| March 31, 2025 | -0.3487 |
| December 31, 2024 | 0.3332 |
| September 30, 2024 | -0.4149 |
| June 30, 2024 | -0.5742 |
| March 31, 2024 | 0.661 |
| December 31, 2023 | -0.4317 |
| September 30, 2023 | -1.271 |
| June 30, 2023 | -0.6831 |
| March 31, 2023 | -0.7621 |
| December 31, 2022 | -0.4282 |
| September 30, 2022 | -0.4627 |
| June 30, 2022 | -0.5056 |
| March 31, 2022 | -0.6713 |
| December 31, 2021 | 2.431 |
| September 30, 2021 | -0.5933 |
| June 30, 2021 | -1.311 |
| March 31, 2021 | -0.6992 |
| December 31, 2020 | -1.095 |
| September 30, 2020 | -1.131 |
| June 30, 2020 | -2.176 |
| Date | Value |
|---|---|
| March 31, 2020 | -2.372 |
| December 31, 2019 | -1.747 |
| September 30, 2019 | -2.088 |
| June 30, 2019 | -2.372 |
| March 31, 2019 | -2.344 |
| December 31, 2018 | -2.55 |
| September 30, 2018 | -1.966 |
| June 30, 2018 | -2.55 |
| March 31, 2018 | -2.174 |
| December 31, 2017 | -4.25 |
| September 30, 2017 | -3.74 |
| June 30, 2017 | -5.27 |
| March 31, 2017 | -4.42 |
| December 31, 2016 | -2.72 |
| September 30, 2016 | -3.06 |
| June 30, 2016 | -5.44 |
| March 31, 2016 | -6.46 |
| December 31, 2015 | -4.25 |
| September 30, 2015 | -5.95 |
| June 30, 2015 | -4.42 |
| March 31, 2015 | -3.91 |
| December 31, 2014 | -5.368 |
| September 30, 2014 | -5.44 |
| June 30, 2014 | -9.35 |
| March 31, 2014 | -6.97 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 0.0858 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 1.010 |
| Veru, Inc. | -0.3032 |
| Eli Lilly & Co. | 7.221 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.623M |
| Revenue (Quarterly) | 0.1901M |
| Total Expenses (Quarterly) | 2.813M |
| Enterprise Value | -10.65M |
| Gross Profit Margin (Quarterly) | 92.32% |
| Profit Margin (Quarterly) | -1.38K% |
| Earnings Yield | -115.4% |
| Normalized Earnings Yield | -115.42 |